New Data Highlights Zio Performance in an Asian Population
In a real-world analysis of 408,470 U.S. patients monitored with iRhythm’s Zio long-term continuous ECG service, median wear time...
eClinical Tech News
Annovis Links Amyloid to Faster Decline in Parkinson’s
Annovis reported that in its Phase 3 study in early Parkinson’s disease (NCT05357989), buntanetap halted cognitive decline across the...
FDA Approves Eylea HD for RVO and Macular Edema Treatment
In the Phase 3 QUASAR trial, EYLEA HD (aflibercept 8 mg) dosed every eight weeks after either three or...
Promising Diabetic Ulcer Treatment Enters Clinical Trial
FibroBiologics will enroll 120 patients across 10 Australian sites in a randomized Phase 1/2 trial of CYWC628, a topically...
Physiotherapy Equipment Market to Surpass $9.45B by 2029
The physiotherapy equipment market generated $6.26 billion in 2023, is estimated at $6.70 billion for 2024, and is projected...
Breakthrough TARA-002 Trial Sees Positive Pediatric Results
In an interim readout from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations, 100% of the eight patients...
NIH Funds Trial for Non-Surgical Knee Osteoarthritis Relief
Steadman Philippon Research Institute and Neuromuscular Dynamics have initiated a randomized, at-home trial in knee osteoarthritis testing an eight-week...
Radiopharm Begins Promising Phase 1 Prostate Cancer Trial
Radiopharm Theranostics has received ethics approval from Australia’s Bellberry HREC to initiate a first-in-human Phase 1 study of RAD...
Annovis Announces FDA Meeting for Parkinson’s, Alzheimer’s
No new efficacy or safety data accompanied Annovis Bio’s update. The company reported two regulatory developments: FDA has scheduled...
HCW Biologics Begins First-in-Human Trial for Autoimmunity
HCW Biologics has dosed the first patient in its multi-center, first-in-human Phase 1 trial of HCW9302 (NCT07049328) in alopecia...